These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 37076483)

  • 21. Long-Lived Immunity in SARS-CoV-2-Recovered Children and Its Neutralizing Capacity Against Omicron.
    Sieber J; Mayer M; Schmidthaler K; Kopanja S; Camp JV; Popovitsch A; Dwivedi V; Hoz J; Schoof A; Weseslindtner L; Szépfalusi Z; Stiasny K; Aberle JH
    Front Immunol; 2022; 13():882456. PubMed ID: 35663948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SARS-CoV-2 Antibodies in Commercial Immunoglobulin Products Show Markedly Reduced Cross-reactivities Against Omicron Variants.
    Lindahl H; Chen P; Åberg M; Ljunggren HG; Buggert M; Aleman S; Smith CIE; Bergman P
    J Clin Immunol; 2023 Aug; 43(6):1075-1082. PubMed ID: 37058198
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
    PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Breakthrough infections with the omicron and delta variants of SARS-CoV-2 result in similar re-activation of vaccine-induced immunity.
    Søraas A; Grødeland G; Granerud BK; Ueland T; Lind A; Fevang B; Murphy SL; Huse C; Nygaard AB; Steffensen AK; Al-Baldawi H; Holberg-Petersen M; Andresen LL; Ågnes C; Ranheim T; Schanke Y; Istre M; Dahl JA; Chopra A; Dudman S; Kaarbø M; Andersen JT; Vaage EB; Tran TT; Vaage JT; Michelsen AE; Müller F; Aukrust P; Halvorsen B; Dahl TB; Holter JC; Lund-Johansen F
    Front Immunol; 2022; 13():964525. PubMed ID: 36159859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced cross-recognition of SARS-CoV-2 Omicron variant by peptide vaccine-induced antibodies.
    Aparicio B; Ruiz M; Casares N; Silva L; Egea J; Pérez P; Albericio G; Esteban M; García-Arriaza J; Lasarte JJ; Sarobe P
    Front Immunol; 2022; 13():1044025. PubMed ID: 36761163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8
    Redd AD; Nardin A; Kared H; Bloch EM; Abel B; Pekosz A; Laeyendecker O; Fehlings M; Quinn TC; Tobian AAR
    mBio; 2022 Apr; 13(2):e0361721. PubMed ID: 35229637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 29. SARS-CoV-2 Omicron BA.1 variant breakthrough infections in nursing home residents after an homologous third dose of the Comirnaty® COVID-19 vaccine: Looking for correlates of protection.
    Torres I; Giménez E; Albert E; Zulaica J; Álvarez-Rodríguez B; Burgos JS; Peiró S; Limón R; Vanaclocha H; Rodado C; Botija P; Sifre A; Tur B; Lozano RA; Orosa I; Vicente-Ruiz M; Carrión RJ; Clari MÁ; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Geller R; Navarro D;
    J Med Virol; 2022 Sep; 94(9):4216-4223. PubMed ID: 35585782
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
    Moyo-Gwete T; Madzivhandila M; Mkhize NN; Kgagudi P; Ayres F; Lambson BE; Manamela NP; Richardson SI; Makhado Z; van der Mescht MA; de Beer Z; de Villiers TR; Burgers WA; Ntusi NAB; Rossouw T; Ueckermann V; Boswell MT; Moore PL
    J Virol; 2022 Aug; 96(15):e0055822. PubMed ID: 35867572
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
    Sheward DJ; Kim C; Ehling RA; Pankow A; Castro Dopico X; Dyrdak R; Martin DP; Reddy ST; Dillner J; Karlsson Hedestam GB; Albert J; Murrell B
    Lancet Infect Dis; 2022 Jun; 22(6):813-820. PubMed ID: 35305699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differential Impact of SARS-CoV-2 Isolates, Namely, the Wuhan Strain, Delta, and Omicron Variants on Erythropoiesis.
    Saito S; Shahbaz S; Sligl W; Osman M; Tyrrell DL; Elahi S
    Microbiol Spectr; 2022 Aug; 10(4):e0173022. PubMed ID: 35943266
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal Tracking of Immune Responses in COVID-19 Convalescents Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other SARS-CoV-2 Variants of Concern.
    Odak I; Schultze-Florey CR; Hammerschmidt SI; Ritter C; Willenzon S; Friedrichsen M; Ravens I; Sikora R; Bayir LM; Gutierrez Jauregui R; Bernhardt G; Stankov MV; Cossmann A; Hansen G; Krey T; Cornberg M; Koenecke C; Behrens GMN; Bošnjak B; Förster R
    Front Immunol; 2022; 13():863039. PubMed ID: 35359969
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evolution of Immune Evasion and Host Range Expansion by the SARS-CoV-2 B.1.1.529 (Omicron) Variant.
    Ren W; Zhang Y; Rao J; Wang Z; Lan J; Liu K; Zhang X; Hu X; Yang C; Zhong G; Zhang R; Wang X; Shan C; Ding Q
    mBio; 2023 Apr; 14(2):e0041623. PubMed ID: 37010428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants.
    Chang MR; Ke H; Coherd CD; Wang Y; Mashima K; Kastrunes GM; Huang CY; Marasco WA
    EBioMedicine; 2022 Jun; 80():104025. PubMed ID: 35533497
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vaccination with the Omicron spike RBD boosts broadly neutralizing antibody levels and confers sustained protection even after acquiring immunity to the original antigen.
    Azuma H; Kawano Y; Shitaoka K; Kawahara T; Ito A; Higashiura A; Kitajima Y; Ohki S; Yasuda T
    Int Immunol; 2023 Apr; 35(4):197-207. PubMed ID: 36413150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection.
    Curlin ME; Bates TA; Guzman G; Schoen D; McBride SK; Carpenter SD; Tafesse FG
    Med; 2022 Dec; 3(12):827-837.e3. PubMed ID: 36198311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
    Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
    Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of antibody responses against SARS-CoV-2 in unvaccinated individuals and vaccinees from Omicron-BA.2 infection in Zhaoqing, Guangdong Province, China.
    Zhang H; Jiang Y; Tan H; Zou L; Zheng Z; Huang Y; Lin S; Su L; Yu J; Deng X; He J; Liu C; Shen C; Li B
    Virol J; 2022 Nov; 19(1):197. PubMed ID: 36434614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.
    Rescigno M; Agrati C; Salvarani C; Giannarelli D; Costantini M; Mantovani A; Massafra R; Zinzani PL; Morrone A; Notari S; Matusali G; Pinter GL; Uccelli A; Ciliberto G; Baldanti F; Locatelli F; Silvestris N; Sinno V; Turola E; Lupo-Stanghellini MT; Apolone G;
    Front Immunol; 2023; 14():1104124. PubMed ID: 36776853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.